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OBJECTIVE—Diabetic foot infection is the predominant predisposing factor to nontraumatic
lower-extremity amputation (LEA), but few studies have investigated which speciﬁc risk factors
are most associated with LEA. We sought to develop and validate a risk score to aid in the early
identiﬁcation of patients hospitalized for diabetic foot infection who are at highest risk of LEA.
RESEARCH DESIGN AND METHODS—Using a large,clinical research database (Care-
Fusion),weidentiﬁedpatientshospitalizedat97hospitalsintheU.S.between2003and2007for
culture-documented diabetic foot infection. Candidate risk factors for LEA included demo-
graphic data, clinical presentation, chronic diseases, and recent previous hospitalization. We
ﬁt a logistic regression model using 75% of the population and converted the model coefﬁcients
to a numeric risk score. We then validated the score using the remaining 25% of patients.
RESULTS—Among 3,018 eligible patients, 21.4% underwent an LEA. The risk factors most
highly associated with LEA (P , 0.0001) were surgical site infection, vasculopathy, previous
LEA, and a white blood cell count .11,000 per mm
3. The model showed good discrimination
(c-statistic0.76)andexcellentcalibration(Hosmer-Lemeshow,P=0.63).Theriskscorestratiﬁed
patients into ﬁve groups, demonstrating a graded relation to LEA risk (P , 0.0001). The LEA
rates (derivation and validation cohorts) were 0% for patients with a score of 0 and ~50% for
those with a score of $21.
CONCLUSIONS—Using a large, hospitalized population, we developed and validated a risk
score that seems to accurately stratify the risk of LEA among patients hospitalized for a diabetic
foot infection. This score may help to identify high-risk patients upon admission.
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L
ower-extremity amputation (LEA) is
one of the complications of diabetes
that is perhaps most feared by pa-
tients with this disease (1) and rightfully
so.TheseLEAsaregenerallytheendpoint
of a characteristic sequence of events: a
foot wound, usually a consequence of
peripheral neuropathy, becomes infected
and does not respond to treatment (2).
More than 60% of nontraumatic LEAs in
theU.S.occuramongpeoplewithdiabetes,
in whom the rate is 6 to 10 times higher
than for people without diabetes (3).
After a ﬁrst LEA, up to 50% of patients
require another amputation within 3–5
years. Furthermore, the 5-year mortality
after LEA is ~50% (4), with the risk con-
siderably higher for diabetic compared
with nondiabetic patients (5).
Considering the substantial morbid-
ity and mortality associated with LEA in
people with diabetes, the ability to identify
which patients hospitalized for a diabetic
foot infection are at highest risk for this
complication could help clinicians direct
special prevention efforts to these indi-
viduals. This information also could help
identify the baseline risk for LEA among
patients admitted to a medical center, al-
lowing fairer comparisons of amputation
rates at different centers. Although the
factors associated with diabetic people de-
veloping a foot ulcer are well deﬁned (1),
risk factors for amputation are less clear.
Previous studies have identiﬁed indepen-
dent risk factors that include (in approxi-
mateorderofoddsratio)ahistoryofafoot
ulcer (6), limb ischemia, underlying bone
involvement, the presence of gangrene
(e.g.,ahigherWagnergrade),deepwounds,
older age, elevated inﬂammatory markers
(7), poor glycemic control (8), a speciﬁc
ethnicity or geographical region (9,10),
nephropathy (8), and retinopathy (6). To
determine whether we could develop and
validate a scoring system to predict the
risk ofLEA,we examined data froma large
group of patients hospitalized with a dia-
betic foot infection.
RESEARCH DESIGN AND
METHODS—Weuseddatafromaclin-
ical research database of patients hospi-
talized at 97 acute-care hospitals in the
U.S. that was compiled by CareFusion
(Department of Clinical Research, Care-
Fusion, Marlborough, MA). The database
includes extensive data in the following
categories: clinical (including diagnoses
and vital signs); laboratory (e.g., chemis-
try, hematology, and microbiology); and
administrative (e.g., demographics, ad-
mission source, length of hospitalization,
and discharge status). Eligible patients
were those discharged from one of the
designated hospitals between 1 January
2003 and 30 June 2007 with a principal
diagnosis (ICD-9-CM) of diabetes and a
secondary diagnosis indicating skin or soft-
tissue infection (including cellulitis, in-
fected ulcer, or surgical-site infection [SSI])
that was culture documented within 48 h
of admission. This study was approved by
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Study design and statistical analysis
We randomly split the study population
intotwogroups:oneformodelderivation
(75% of the population) and the other
for model validation (the remaining 25%).
Candidate predictor variables used in the
modelweredemographicdata,ahistoryof
previous health care–associated infection,
clinicalpresentation,concomitantchronic
disease(s), previous LEA, and type of skin
or soft-tissue infection (cellulitis, ulcer or
other infection, or SSI). Our outcome
measure of interest was LEA during the
index hospitalization, which was identi-
ﬁedbyICD-9procedurecodes(841.1am-
putation, toe; 841.2 amputation, foot;
841.3 disarticulation, ankle; 841.4 amputa-
tion, Malleoli; 841.5 amputation, knee, be-
low NEC [not elsewhere classiﬁed]; 841.6
disarticulation, knee; and 841.7 amputa-
tion, knee, above).
Using the derivation cohort, we con-
ducted univariate analyses to determine
the proportion of patients with each can-
didate predictor who underwent an LEA.
We thenﬁtastepwisemultivariatelogistic
regression model to identify independent
predictors of LEA and to estimate their
relative predictive weights (coefﬁcients).
Using previously published methods, we
converted the coefﬁcients for the inde-
pendent predictors into a simpliﬁed risk
score system (11). Speciﬁcally, we calcu-
latedthenumberofpointsassignedtoeach
variable by dividing its regression coefﬁ-
cient by the smallest coefﬁcient in the
model then rounded this quotient to the
nearest whole number. We then calculated
each subject’s LEA risk score by summing
up the points of all variables present on
admission.Wethenvalidatedtheriskscore
system using the remaining 25% of the
population.
We assessed model discrimination
using the c-statistic, which deﬁnes how
well a model or prediction rule can dis-
criminate between patients who do and
do not have an event and measures how
well a clinical prediction rule correctly
rankspatientsinorderbyrisk.Weassessed
model calibration using the Hosmer-
Lemeshow goodness-of-ﬁt test, which as-
sesses whetherthe observedand expected
event rates match in subgroups of the
model population. The test speciﬁcally
identiﬁes subgroups as the deciles of ﬁtted
risk values, and models with similar ex-
pectedandobservedeventrates(i.e.,alarge
P value) are considered to be well calibra-
ted. We then used the Cochran-Armitage
trending statistic, which modiﬁes the x
2
test to incorporate a suspected ordering, to
assess the ability of the risk score system to
differentiatelow-riskfromhigh-riskpatients
Table 1—Characteristics for patients in the derivation and the validation cohorts
Variable
Derivation
cohort
Validation
cohort
n 2,230 788
Mortality (death during hospitalization) 30 (1.3) 10 (1.3)
Amputation during index hospitalization 463 (20.8) 184 (23.3)
Median age (years [ﬁrst through third quartiles]) 60 (50–71) 60 (50–71)
Male sex 1,359 (60.9) 493 (62.6)
Previous admission within #30 days 214 (9.6) 68 (8.6)
Transferred from an acute-care hospital 19 (0.9) 8 (1.0)
Transferred from a skilled nursing facility 72 (3.2) 32 (4.1)
Race/ethnicity
White 1,574 (70.6) 593 (75.3)
Black 420 (18.8) 115 (14.6)
Other 236 (10.6) 80 (10.2)
Comorbidities
Congestive heart failure 522 (23.4) 171 (21.7)
History of coronary disease 532 (23.9) 193 (24.5)
Immunosuppressive medication 73 (3.3) 33 (4.2)
Cancer 46 (2.1) 12 (1.5)
Peripheral vascular disease 807 (36.2) 287 (36.4)
Chronic liver disease 31 (1.4) 9 (1.1)
Chronic lung disease 232 (10.4) 97 (12.3)
Previous stroke 234 (10.5) 74 (9.4)
Chronic renal disease 445 (20.0) 153 (19.4)
History of amputation 611 (27.4) 203 (25.8)
Renal dialysis treatment 53 (2.4) 23 (2.9)
Type of skin and soft-tissue infection
Cellulitis 1,788 (80.2) 629 (79.8)
Infected ulcer 360 (16.1) 129 (16.4)
Surgical site 82 (3.7) 30 (3.8)
Severe infection clinical presentation
Systolic blood pressure ,100 mmHg 293 (13.1) 110 (14.0)
Temperature ,96°F or .100.5°F 681 (30.5) 238 (30.2)
Pulse ,49 or .125 bpm 128 (5.7) 40 (5.1)
Respiration ,10 or .29 breaths per minute 86 (3.9) 35 (4.4)
Altered mental status 173 (7.8) 66 (8.4)
Laboratory results
Albumin ,2.8 g/dL 237 (10.6) 95 (12.1)
Blood urea nitrogen .40 mg/dL 399 (17.9) 121 (15.4)
Creatinine .3 mg/dL 176 (7.9) 65 (8.2)
Sodium .145 mEq/dL 24 (1.1) 11 (1.4)
Total bilirubin .0.8 mg/dL 206 (9.2) 89 (11.3)
pO2 ,55 or .140 or O2 sat ,90% 37 (1.7) 10 (1.3)
Prothrombin time international normalized ratio
.1.2 or prothrombin time .14 s 209 (9.4) 68 (8.6)
Bands on leukocyte differential .13% 80 (3.6) 29 (3.7)
White blood cell count .11,000 per mm
3 1,037 (46.5) 397 (50.4)
Glucose on admission (mg/dL)
#70 100 (4.5) 35 (4.4)
71–135 331 (14.8) 124 (15.7)
136–240 717 (32.2) 236 (29.9)
.240 1,082 (48.5) 393 (49.9)
Data are n (%), unless otherwise indicated. The P values for each variable is .0.05, indicating that the
derivation and validation cohorts are similar.
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LEA risk scorein a graded response. All analyses were con-
ducted using Statistical Analysis System
(version 9.01; SAS Institute, Cary, NC).
RESULTS
Patient characteristics
Among hospitalized patients, 3,018 met
our inclusion criteria for a diabetic foot
infection, with cellulitis (in 80%) and an
infected ulcer (16%) being the most com-
mon diagnoses. We used 2,230 patients
for the derivation cohort and 788 for the
validation cohort; all baseline character-
istics were similar between the two co-
horts (Table 1). A total of 646 (21.4%)
patients underwent an LEA during their
index hospitalization; the number (and
rate) in the derivation cohort was 463
(20.8%) compared with 183 (23.2%) for
the validation cohort. For those patients
undergoing an LEA, the median time
from admission to amputation was 4 days,
with an interquartile range of 2–7 days. A
previous LEA of some type was noted in
~27% of patients in the derivation cohort
and 26% in the validation cohort.
For the entire study cohort, the pa-
tients who underwent an LEA were sig-
niﬁcantly older (median age in years
[interquartile range] 62 [53–72] vs. 60
[50–71]; P , 0.0001), and their in-
hospital mortality rate was signiﬁcantly
higher(2.3vs.1.1%;P,0.05)compared
with patients who did not require am-
putation. The most common ﬁnding on
culturewasapolymicrobial(twoormore
different microorganisms) infection,
whichaccountedfor~57%ofallpatients.
A detailed accounting of pathogen dis-
tribution is shown in Supplementary
Appendix A.
Univariate analysis of risk factors
associated with LEA
As shown in Table 2, in the derivation co-
hort the univariate analysis revealed that
thefollowingfactorsweresigniﬁcantlyas-
sociated with LEA (P , 0.05): older age;
male sex; transfer from another hospital
or nursing home; previous LEA; coro-
nary,renal,orperipheralvasculardisease;
low serum albumin; elevated values for
white blood cell count, prothrombin
time or international normalized ratio,
or creatinine; elevated body temperature;
the presence of a foot ulcer; and the pres-
ence of an SSI.
Multivariable LEA predictive model
Using stepwise regression analysis, we
found 11 independent predictors of LEA
(Table 3). The most highly signiﬁcant
(P , 0.0001) were SSI, vasculopathy,
previous LEA, and white blood cell count
.11,000 per mm
3. The predictive model
developed using these predictors had very
good discrimination (c-statistic 0.76) and
excellent calibration between predicted and
observed LEA rates (Hosmer-Lemeshow
testshowingthattheydidnotsigniﬁcantly
differacrossriskdeciles;P=0.63)(Fig.1).
Patients in the highest risk decile had a
predicted probability of LEA of 59.4%
and an observed LEA rate of 58.7%,
whereas those in the lowest decile had a
predictedprobabilityof LEA of 4% and an
observed LEA rate of 5%. The predictive
Table 2—Univariate analysis of risk factors associated with LEA in the derivation cohort
Variable
Derivation cohort
(% [n LEA/n evaluable])
(n =2 , 2 3 0 ) P*
n cases 20.8 (463/2,230)
Mortality (death during hospitalization) 33.3 (10/30) 0.1094
Age $50 years 23.1 (394/1,708) ,0.0001
Male sex 22.3 (303/1,359) 0.0282
Previous admission #30 days 24.8 (53/214) 0.1322
Transferred from an acute-care hospital 63.2 (12/19) 0.0001
Transferred from a skilled nursing facility 40.3 (29/72) 0.0002
Comorbidities
Congestive heart failure 24.3 (127/522) 0.0227
History of coronary disease 26.1 (139/532) 0.0006
Immunosuppressive medication 26.0 (19/73) 0.3032
Cancer 23.9 (11/46) 0.5829
Peripheral vascular disease 32.2 (260/807) ,0.0001
Chronic liver disease 25.8 (8/31) 0.5033
Chronic lung disease 24.1 (56/232) 0.1993
Previous stroke 23.9 (56/234) 0.2025
Chronic renal disease 28.8 (128/445) ,0.0001
History of amputation 31.3 (191/611) ,0.0001
Renal dialysis treatment 41.5 (22/53) 0.0005
Type of skin and soft tissue infection ,0.0001
Cellulitis 16.9 (302/1,788)
Infected ulcer 32.8 (118/360)
Surgical site 52.4 (43/82)
Acute clinical presentation
Systolic blood pressure ,100 mmHg 24.6 (72/293) 0.0892
Temperature ,96°F or .100.5°F 27.0 (184/681) ,0.0001
Pulse ,49 or .125 bpm 24.2 (31/128) 0.3138
Respiration ,10 or .29 breaths per minute 25.6 (22/86) 0.2776
Altered mental status 23.7 (41/173) 0.3293
Laboratory results
Albumin ,2.8 g/dL 36.7 (87/237) ,0.0001
Blood urea nitrogen .40 mg/dL 23.6 (94/399) 0.1341
Creatinine .3 mg/dL 35.8 (63/176) ,0.0001
Sodium .145 mEq/dL 25.0 (6/24) 0.6133
Total bilirubin .0.8 mg/dL 23.8 (49/206) 0.2791
pO2 ,55 or .140 or O2 sat ,90% 21.6 (8/37) 0.8398
Prothrombin time international normalized
ratio .1.2 or prothrombin time .14 s 37.8 (79/209) ,0.0001
Bands on leukocyte differential .13% 26.3 (21/80) 0.2092
White blood cell count .11,000 per mm
3 30.3 (314/1,037) ,0.0001
Glucose on admission (mg/dL) 0.0603
#70 12.0 (12/100)
71–135 18.1 (60/331)
136–240 22.0 (158/717)
.240 21.5 (233/1,082)
*Fisher exact test.
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Lipsky and Associatesmodel yielded a good calibration when
applied to the validation cohort (Hosmer-
Lemeshow test; P =0 . 3 3 ) .
Simpliﬁed risk score strata
For each patient, we summed all the vari-
ables present on admission to create an
LEA risk score. We then grouped the risk
scoresinto ﬁve risk strata. The use of a ﬁve-
level risk strata allows easy application of
risk stratiﬁcation for comparisons of out-
comes. LEA rates in the derivation and
validation cohorts increased signiﬁcantly
by risk score strata (P , 0.0001 by the
Cochran-Armitage trending test for both
derivationandvalidationcohorts)(Fig.2).
For the derivation cohort, the risk of LEA
for patients aged ,50 years and without
anyoftheother10factorsintheriskscore
system was essentially zero. In contrast,
for those whose score was $21, LEA risk
was ~50%. The ﬁndings in the validation
cohort were similar to those in the deriva-
tion cohort.
CONCLUSIONS—In thislarge cohort
of patients hospitalized for a diabetic foot
infection,more than one-ﬁfthrequired an
LEA. In reviewing numerous clinical and
laboratory variables present at hospital
admission in our derivation cohort, we
identiﬁed 11 signiﬁcant independent risk
factors for LEA. By rounding the logistic
regression coefﬁcients into integers, we
developed a simple LEA risk score system
with ﬁve strata that we demonstrated was
highly predictive of the risk for LEA. Us-
ing the patients in the validation cohort,
we were then able to demonstrate that this
risk score was indeed valid and well cali-
brated.
Most of the factors included in our
risk score have been reported as risks
for LEA in smaller, previously published
studies (7,12,13). The presence of infec-
tion and peripheral vascular disease are
the most powerful predictors. Most pa-
tients with diabetic foot ulcers do not
have a fever or leukocytosis (14), which
deﬁne a severe infection according to the
Infectious Diseases Society of America
and the International Working Group
ontheDiabeticFootcriteria.Thesesevere
diabetic foot infections are associated
with a greater risk of LEA than those of
mild or moderate severity. Previous stud-
ies (15,17) also have identiﬁed renal in-
sufﬁciency as being associated with an
increased risk of amputations. Other
studies have identiﬁed increasing age
(18), malesex(16), and hypoalbuminemia
(19) as risks for LEA. Likewise, a previous
LEA is a strong risk factor predicting the
need for another amputation (12). In
none of these previous studies, however,
did the authors attempt to construct a
scoring system to predict amputation
risk for both men and women.
In a previous study (20), we showed
that patients with SSIs who were trans-
ferred from another acute-care facility
had worse clinical and economic out-
comes, perhaps because patients with in-
fections of greater severity are more likely
to be transferred to hospitals with more
intensive resources or greater expertise. A
recent meta-analysis (21) demonstrated a
directassociationbetweenhyperglycemia
(as measured by hemoglobin A1c)a n d
LEA. Unfortunately, we did not have he-
moglobin A1c values on most of our pa-
tients, but we did note a nonsigniﬁcant
Table 3—Multivariable model and risk score for LEA
Risk factor Coefﬁcient
Odds ratio
(95% CI) P
Risk score
weight*
Chronic renal disease or creatinine
.3 mg/dL† 0.1372 1.15 (0.89–1.49) 0.2998 1
Male sex† 0.1988 1.22 (0.97–1.54) 0.0963 1
Temperature ,96°F or .100.5°F 0.2830 1.33 (1.05–1.68) 0.0187 2
Age $50 years 0.5477 1.73 (1.28–2.34) 0.0004 4
Infected ulcer versus cellulitis 0.5168 1.68 (1.27–2.21) 0.0002 4
History of amputation 0.5020 1.65 (1.29–2.11) ,0.0001 4
Albumin ,2.8 g/dL 0.6203 1.86 (1.35–2.56) 0.0001 5
History of peripheral vascular disease 0.7485 2.11 (1.66–2.69) ,0.0001 5
White blood cell count
$11 (1,000 per mm
3) 0.9596 2.61 (2.07–3.30) ,0.0001 7
Surgical site vs. cellulitis 1.3845 3.99 (2.44–6.55) ,0.0001 10
Transferred from other acute-care facility 1.6418 5.16 (1.78–15.02) 0.0026 12
*We used the method described by Sullivan et al. (11) to calculate the risk score weight: Step 1: divide each
regression coefﬁcient by the smallest coefﬁcient in the model (in our model, this is chronic renal disease or
creatinine.3mg/dL).Step2:roundthisquotienttothenearestwholenumber.Forexample,tocalculatethe
score weight of male sex, we divided its coefﬁcient of 0.1988 by 0.1371, resulting in a quotient of 1.44.
Rounding this quotient to its nearest integer resulted in 1 for the score weight of this variable. We then
calculated each subject’s overall LEA risk score by summing the points of all variables present on admission.
†We retained these two variables for clinical plausibility despite the fact that they are not statistically sig-
niﬁcant at the 0.05 level in the model.
Figure 1—Comparison of the predicted probability of LEA against the observed amputation rate
for both derivation and validation cohorts, by decile. The diagonal line represents perfect cor-
relation of predicted and observed LEA rates. Model Hosmer-Lemeshow goodness-of-ﬁtt e s tx
2 =
6.2,P=0.63vs.x
2=9.2,P=0.33forthederivationvs.thevalidationcohorts,indicatingexcellent
ﬁto ft h em o d e l .
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LEA risk scoretrend toward higher amputation rates in
those with increased blood glucose levels
on admission. All of our patients had an
infection; therefore, that variable was not
among those included in our scoring sys-
tem. It is noteworthy that the type of in-
fection was associated with amputation
risk, with SSIs at the highest risk, fol-
lowed by infected ulcers,when compared
with cellulitis. Our assumption is that
these SSIs may be associated with failed
lower-extremity bypass procedures. We
found no other studies that investigated
the risk of adverse outcomes in patients
with an infected ulcer compared with cel-
lulitis or SSIs. We did ﬁnd other studies
(7,14,22,23) that reported that deep in-
fections (especially those involving bone)
and necrotizing infections more often re-
sulted in amputations.
The simpliﬁed ﬁve risk strata that
we devised correlated strongly with LEA
rates. This may have important clinical
implicationsonhowtoallocateresources.
In particular, a patient with a low score
may need fewer medical resources than a
p a t i e n tw i t hah i g hL E Ar i s ks c o r e .A tt h e
other extreme, to try to avoid the tragedy
of amputation, health care providers
should concentrate efforts on a patient
with a risk score of .21, who has a 50%
chance of an LEA. Our ﬁnding that pa-
tients transferred from another acute-
care hospital had the highest odds ratio
for LEA highlights the need of risk ad-
justment to appropriately evaluate out-
comes for hospitals treating the most
severe patients. Because LEA rates are
sometimes used to compare quality of
care for patients with diabetic foot com-
plications, our risk adjustment score
could be used to ensure that centers treat-
ing higher-risk patients are not unfairly
penalized. Furthermore, although this
has not been tested, the score might be
helpfultocliniciansindecidingwhichpa-
tients with diabetic foot infections may
need to be hospitalized. The LEA risk
scor esy stemh astheb en eﬁtofb e i ngs i m -
ple to use; each of the risk factors is readily
available, usually at the time of admission
or soon afterward.
Our study is limited by the fact that
our analysis was retrospective, and, al-
though fairly inclusive, we could have
missed potentially signiﬁcant factors. For
example, the individual reasons for am-
putation and whether amputation was
electiveorurgentwerenotcapturedinthe
database. One major risk factor that we
did not capture that could have an effect
on our risk score is a history of a previous
lower-extremity revascularization proce-
dure, which was a signiﬁcant factor in
other reports (24,25). Selection bias is
anotherpotentiallimitationwhenusingad-
ministrative data to identify patients with
skin or soft-tissue infections. To minimize
potential bias related to the use of ICD-9
coding, we limited our study to culture-
conﬁrmed infections.
Inconclusion, we usedalarge clinical
database to develop and validate a risk
scorethatseemstoaccuratelystratifyLEA
risk among patients hospitalized for a di-
abetic foot infection. This score may help
clinicians identify patients at highest risk
of LEA upon admission. Once patient iden-
tiﬁcation is achieved, methods to reduce
therisk canbe investigated.We would like
to see our risk score validated prospec-
tively, including in patients treated on an
outpatient basis.
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